Management ChangeJun 11, 2026, 08:46 AM
Palisade Bio Appoints Robert Baltera and Jordan Zwick to Board
AI Summary
Palisade Bio, Inc. announced the appointment of Robert Baltera and Jordan Zwick to its Board of Directors. These additions are expected to strengthen the board with extensive expertise in biotechnology leadership, strategic transactions, capital markets, and corporate governance. The company is continuing to advance its lead program, PALI-2108, a PDE4 inhibitor prodrug, toward Phase 2 clinical development for inflammatory bowel diseases.
Key Highlights
- Palisade Bio appointed Robert Baltera to its Board of Directors, bringing over three decades of biopharmaceutical leadership.
- Mr. Baltera previously served as CEO of Amira Pharmaceuticals, which was sold to Bristol-Myers Squibb for $475 million.
- Jordan Zwick was also appointed to the Board, bringing expertise in corporate strategy, business development, and capital markets.
- Mr. Zwick is Co-Founder and Chief Business Officer of Mirador Therapeutics and advised Prometheus Biosciences prior to its acquisition by Merck.
- The new directors strengthen the board with expertise in company building, strategic transactions, and capital markets.
- The company's lead program, PALI-2108, is advancing toward Phase 2 clinical studies in ulcerative colitis and Crohn's disease.
Price Impact
More from PALI